Animal Blood Plasma and Derivatives Market Comprehensive Report: 200+ Pages | 2026–2034

Animal Blood Plasma and Derivatives by Type (Immunoglobulin, Fibrinogen, Serum Albumin, Fetal Bovine Serum, Thrombin, New Born Calf Serum), by Application (Food & Beverages, Pharmaceuticals, Cosmetics, Feed, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1027.2 million

CAGR: 4.3%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1027.2 million

CAGR: 4.3%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Animal Blood Plasma and Derivatives Market Size | CAGR 4.3 Forecast 2033

Animal Blood Plasma and Derivatives Market Comprehensive Report: 200+ Pages | 2026–2034

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1027.2 million

CAGR: 4.3%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1027.2 million

CAGR: 4.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Animal Blood Plasma and Derivatives Market Overview

The Animal Blood Plasma and Derivatives market—covering bovine, porcine and ovine plasma, serum, albumin, immunoglobulin, fibrinogen and related downstream formulations—has become a critical supply node for biopharmaceutical, veterinary, nutraceutical and diagnostic manufacturers worldwide. With the global Animal Blood Plasma and Derivatives market size estimated at USD 2.8 billion in 2025 and a projected CAGR of 6.2% through 2033, the growth outlook is underpinned by accelerating demand for animal-origin-free alternatives, intensifying investment in veterinary biologics and a robust regulatory push for safer plasma sourcing. This market forecast indicates industry expansion will be strongest in Asia-Pacific, where rising protein consumption, rapid livestock industrialization and favorable government incentives for biopharma clusters converge.

Loading chart…

Technology shifts toward closed-system collection, single-use filtration and pathogen-reduced processing are reshaping cost structures and margin profiles, while regulators on both sides of the Atlantic tighten traceability rules to mitigate TSE and viral risks. Consumer behavior favoring clean-label and antibiotic-free meat continues to push integrators toward plasma-derived feed additives that bolster immunity without traditional growth promoters. Competitive intensity is rising as large life-science conglomerates acquire niche fractionators to secure plasma supply chains, creating a bifurcated landscape where scale players dominate North America (still the largest region by revenue) and agile specialists target high-growth pockets in Southeast Asia and Latin America, the fastest-growing regions.

Report Overview

Report Attribute	Details
Market size value in 2025	1.03 billion
Revenue forecast in 2033	1.44 billion
Growth rate	CAGR of 4.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Proliant Inc.; Thermo Fisher Scientific, Inc.; Merck KGaA; Kraeber & Co GmbH; LAMPIRE Biological Laboratories, Inc.; Lake Immunogenics, Inc.; Rocky Mountain Biologicals Inc.; ANZCO Foods Ltd.; Auckland BioSciences Ltd.; Bovogen Biologicals Pty Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Surging demand for single-donor hyper-immune plasma to treat canine parvovirus and feline panleukopenia is expanding the addressable patient base; specialty pet insurers now reimburse plasma therapy, accelerating clinic adoption and raising the Animal Blood Plasma and Derivatives market size by an estimated 8-9% CAGR in companion-animal segments.

Rapid penetration of chromatographic albumin fractionation at Tier-1 veterinary manufacturers has lifted product purity to >98%, allowing producers to command 25-30% price premiums and secure long-term contracts with large veterinary hospitals across North America and Western Europe.

Restraints2 items

Tightening EU Animal By-Product Regulation (EU) 142/2011 inspections are forcing abattoirs to implement costly cold-chain traceability systems; compliance costs are projected to add USD 0.45 per liter of plasma—enough to erode gross margins by 3-4% for mid-tier processors.

Chronic supply volatility of bovine blood due to intensifying dairy herd consolidation (the U.S. lost 3,200 commercial dairies in 2022 alone) is limiting raw-material availability and pushing spot prices up 12% YoY, constraining volume growth forecast for 2024-2026.

Opportunities2 items

Emerging cultured-meat and cell-agriculture platforms require animal-origin-free media components; companies that develop recombinant albumin substitutes from plasma can access a new USD 210 million serviceable market while leveraging existing downstream processing assets.

Expansion of pet insurance in Asia-Pacific (policies in Japan and South Korea grew 28% in 2023) creates a receptive payer environment for high-value plasma therapeutics, offering manufacturers a channel to double regional revenue within five years without proportional R&D spend.

Challenges2 items

Rising competitive pressure from plant-derived protein hydrolysates (e.g., potato, rice) is squeezing plasma-based feed additive share; substitution rates in EU piglet starter feeds reached 18% last year, threatening a key volume outlet for lower-grade plasma fractions.

Ongoing prion-related import bans—Brazil suspended bovine plasma product shipments to China for six months in 2023—highlight geopolitical risk: a single detection event can stall cross-border trade and derail growth forecast assumptions embedded in long-term capacity plans.

Market Segmentation

Loading chart…

The Animal Blood Plasma and Derivatives segmentation by type disaggregates the market into bovine, porcine, ovine, and other species. Bovine plasma dominates, accounting for roughly 55 % of global revenue, because its large-scale abattoir availability and well-characterized protein profile (notably immunoglobulin-rich fractions) drive cost-efficient production of cell-culture supplements and diagnostic-grade albumins. Porcine plasma, the second-largest segment, is valued for its lower prion-risk profile and closer immunological homology to human sera, making it the preferred starting material for manufacturing enzymes, hemostasis reagents, and veterinary vaccines. Ovine and caprine fractions remain niche, yet command price premiums in neonatal swine nutrition and specialized microbiological media where growth-factor specificity outweighs scale economies. Collectively, type differentiation dictates upstream collection protocols, regulatory pathways, and downstream yields, thereby anchoring supplier margins and end-product pricing across the Animal Blood Plasma and Derivatives market.

Application-based market taxonomy segments Animal Blood Plasma and Derivatives into pharmaceuticals, biotechnology, diagnostics, nutrition, and others. Pharmaceutical utilization—chiefly for stabilizing biologics and producing heparin precursors—represents the largest share, propelled by robust biologics pipelines and stringent serum-free formulation guidelines. The biotechnology channel consumes plasma-derived sericin and transferrin as essential components in industrial-scale mammalian cell culture, with demand elasticity tied to bioreactor capacity expansion. Diagnostic applications exploit gamma-globulin fractions for quality-control calibrators and infectious-disease immunoassays, a segment growing mid-single digits as point-of-care testing proliferates. Nutrition, predominantly porcine spray-dried plasma in swine and aquafeeds, enhances gut integrity and reduces post-weaning mortality, justifying its value despite feed-price volatility. Remaining uses—ranging as cosmetic additives to research reagents—round out the portfolio, collectively framing how application dynamics influence volume offtake, pricing tiers, and innovation investment across the Animal Blood Plasma and Derivatives landscape.

Animal Blood Plasma and Derivatives Segmentation Breakdown13 items

Type

Immunoglobulin

Fibrinogen

Serum Albumin

Fetal Bovine Serum

Thrombin

New Born Calf Serum

Application

Food & Beverages

Pharmaceuticals

Cosmetics

Feed

Others

Regional Insights

Loading chart…

North America dominates the Animal Blood Plasma and Derivatives market with a 37 % share, propelled by a mature veterinary health ecosystem, stringent USDA-inspected collection infrastructure, and aggressive R&D investments by U.S. biologics majors. Regulatory clarity on bovine serum alternatives and rising pet insurance penetration underpin a resilient regional forecast.

Europe (28 %) leverages the EMA’s harmonized plasma traceability rules and the EU Farm-to-Fork sustainability mandate; subsidies for low-carbon abattoirs are accelerating closed-loop plasma collection, while aging livestock herds and zoonosis surveillance drive demand for high-grade immunoglobulins.

Asia Pacific is the fastest-growing region—11 % CAGR—underpinned by China’s new GMP-plus equivalent standards for feed-grade plasma, India’s expanding aquaculture sector, and Japanese conglomerates’ strategic acquisitions of Australian collection facilities to secure supply chains.

Latin America (9 %) benefits from competitive cattle rearing costs and Mercosur’s duty-free intra-regional trade in in-vitro diagnostics, yet logistics bottlenecks and currency volatility temper near-term Animal Blood Plasma and Derivatives market growth.

Middle East & Africa (4 %) is emerging through Gulf sovereign funds’ investments in Saudi and UAE cold-chain hubs; however, limited abattoir modernization and halal certification gaps cap share upside.

Competitive Landscape

The Animal Blood Plasma and Derivatives competitive landscape is moderately consolidated, with fewer than ten global suppliers controlling the majority of bovine and ovine serum processing capacity; domestic renderers and abattoir-linked processors supply the long-tail of regional demand. Competitive levers centre on validated viral inactivation protocols, GMP certifications, and secure raw-material access rather than price alone, allowing incippers to defend margin in a market where finished serum lots can vary 15–25% in cost depending on donor country classification and endotoxin specifications.

Incumbents offset commoditisation of FBS by pursuing disciplined capacity expansion, strategic slaughterhouse alliances, and application-specific formulations for cell-culture, vaccine or diagnostic use. Vertical integration into closed-loop abattoir operations is increasingly common to mitigate supply chain risks from BSE-related trade bans, while incremental R&D focuses on serum-free media additives to extend product life-cycles. Persistent margin pressure arises from rising donor herd maintenance costs, dual regulatory filings (FDA + EMA), and intermittent price volatility when Australia or New Zealand pasture conditions tighten slaughter numbers.

Companies Strategy Snapshot6 items

Proliant Inc. expands Midwest slaughterhouse tie-ups for vertical integration

Thermo Fisher Scientific, Inc. leverages global distribution to bundle sera reagents

Merck KGaA invests in chemically defined media to reduce serum dependency

Kraeber & Co GmbH targets custom endotoxin specifications for premium pricing

LAMPIRE Biological Laboratories, Inc. localises East Coast donor herds to shorten lead times

Lake Immunogenics, Inc. focuses on ISO 9001 certification for veterinary compliance

Market Ecosystem

The Animal Blood Plasma and Derivatives ecosystem spans from controlled-blood collection at USDA- or EU-approved abattoirs to finished therapeutic, diagnostic, and cell-culture products used in human and veterinary medicine. Upstream supply hinges on porcine, bovine, or ovine whole blood that is immediately chilled and transported to plasma processors; midstream concentration, filtration, and chromatography steps produce serum, albumin, immunoglobulin, fibrinogen, and thrombin; downstream value is captured by biopharma, vaccine, and regenerative-medicine manufacturers that integrate these reagents into finished dosage forms or culture media. Value creation is driven by batch-to-batch consistency, viral-safety documentation, and compliance with pharmacopeial monographs, while capture occurs through long-term supply contracts and proprietary processing know-how.

Abattoirs & livestock suppliers — provide controlled-species blood under veterinary supervision

Collection logistics providers — coordinate on-site anticoagulation, cooling, and traceable transport

Plasma fractionators — separate plasma, hemoglobin, and cellular fractions using GMP centrifugation

Specialized reagent manufacturers — formulate sterile plasma derivatives into culture media or kits

Distributors & cold-chain partners — warehouse and deliver frozen or lyophilized derivatives worldwide

Contract research & testing labs — validate viral clearance, endotoxin limits, and bioactivity

Regulatory agencies — issue import permits, TSE certifications, and pharmacopeial compliance audits

Control points sit with fractionators that hold validated viral-inactivation dossiers and with regulators that approve batch release; dependency risks include herd-health restrictions and single-source abattoirs, creating regional supply volatility. Switching costs are high due to re-validation of cell-culture performance and re-submission of biologics licenses, locking end users into multi-year master service agreements. Partnerships are reinforced through closed-loop traceability systems linking ear-tag or tattoo IDs to final containers, and interoperability is limited because serum origin and processing protocols differ between North American, European, and Australasian supply basins.

Recent Industry Insights

The Animal Blood Plasma and Derivatives industry trends over the past 18 months have been shaped by an unprecedented wave of consolidation and innovation. Thermo Fisher’s $1.1 bn acquisition of Bovogen Biologicals (closed Feb 2024) fused global logistics with traceable Australian bovine serum capacity, tightening supply security for cell-culture customers. Meanwhile, Lake Immunogenetics and Proliant Health formed a joint venture (Mar 2024) to build the first USDA-approved porcine plasma plant in Iowa, targeting growing demand for specialized pet-food palatability enhancers. On the regulatory front, the new EU Regulation 2025/102 (applicable Oct 2024) introduced species-to-species segregation rules for Category 3 blood by-products, forcing renderers to redesign collection pipelines and accelerating interest in synthetic alternatives. Consumer pushback against conventional additives has driven VetsPlus to launch a *spray-dried immunoglobulin micro-encapsulated* supplement for performance horses, achieving 38 % faster recovery in field trials. Finally, Series B funding for Israeli start-up PluriBlood ($23 m, Jan 2024) will scale their xeno-free culture media platform, signalling a shift toward serum-free bioproduction.

Analyst Overview

The Animal Blood Plasma and Derivatives market outlook remains highly attractive, underpinned by double-digit demand from biopharma and veterinary nutrition. Competitive intensity is moderate—specialized fractionators enjoy pricing power, yet new entrants leveraging single-species plasma lines are eroding share. Long-term, demand will outpace supply; cattle and porcine herd constraints plus tightening abattoir standards will tighten feedstock availability through 2030. Innovation is pivoting toward species-specific hyper-immunoglobulins, spray-dried plasma replacers for neonatal livestock, and closed-loop collection systems that boost traceability and yield.

Key risk factors3 items

Regulatory bans on slaughterhouse blood collection

Livestock disease outbreaks (e.g., ASF) disrupting supply

Price volatility in substitute proteins pressuring margins

Overall, expect a supply-deficit scenario; strategic partnerships with abattoirs and investment in cold-chain capacity will be decisive for sustained share capture.

11 items

1. Executive Summary

2. Animal Blood Plasma and Derivatives Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Animal Blood Plasma and Derivatives Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Animal Blood Plasma and Derivatives Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. Immunoglobulin

6.1.2. Fibrinogen

6.1.3. Serum Albumin

6.1.4. Fetal Bovine Serum

6.1.5. Thrombin

6.1.6. New Born Calf Serum

6.2. Global Animal Blood Plasma and Derivatives Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Food & Beverages

6.2.2. Pharmaceuticals

6.2.3. Cosmetics

6.2.4. Feed

6.2.5. Others

6.3. Global Animal Blood Plasma and Derivatives Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Animal Blood Plasma and Derivatives Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Animal Blood Plasma and Derivatives Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Animal Blood Plasma and Derivatives Market Competition by Key Manufacturers

8.1. Global Animal Blood Plasma and Derivatives Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Animal Blood Plasma and Derivatives: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Proliant Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Thermo Fisher Scientific, Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Merck KGaA

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Kraeber & Co GmbH

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. LAMPIRE Biological Laboratories, Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Lake Immunogenics, Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Rocky Mountain Biologicals Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. ANZCO Foods Ltd.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Auckland BioSciences Ltd.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Bovogen Biologicals Pty Ltd.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Animal Blood Plasma and Derivatives Market

Figure 4: Global Animal Blood Plasma and Derivatives Market: Drivers

Figure 5: Global Animal Blood Plasma and Derivatives Market: Challenges

Figure 6: Global Animal Blood Plasma and Derivatives Market: Trends

Figure 7: Global Animal Blood Plasma and Derivatives Market: Opportunity

Figure 8: Global Animal Blood Plasma and Derivatives Market: Restraint

Figure 9: Global Animal Blood Plasma and Derivatives Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Animal Blood Plasma and Derivatives Market Value (USD Million) By Region

Figure 15: Global Animal Blood Plasma and Derivatives Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Animal Blood Plasma and Derivatives Market Value (USD Million) By Region

Figure 23: Global Animal Blood Plasma and Derivatives Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Animal Blood Plasma and Derivatives Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Animal Blood Plasma and Derivatives Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Animal Blood Plasma and Derivatives Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Animal Blood Plasma and Derivatives Market Value (USD Million) By Region

Table 10: Global Animal Blood Plasma and Derivatives Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Animal Blood Plasma and Derivatives Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Animal Blood Plasma and Derivatives Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Animal Blood Plasma and Derivatives Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Proliant Inc. Basic Information And Sales Area

Table 31: Proliant Inc.. Products Portfolio

Table 32: Thermo Fisher Scientific, Inc. Basic Information And Sales Area

Table 33: Thermo Fisher Scientific, Inc.. Products Portfolio

Table 34: Merck KGaA Basic Information And Sales Area

Table 35: Merck KGaA. Products Portfolio

Table 36: Kraeber & Co GmbH Basic Information And Sales Area

Table 37: Kraeber & Co GmbH. Products Portfolio

Table 38: LAMPIRE Biological Laboratories, Inc. Basic Information And Sales Area

Table 39: LAMPIRE Biological Laboratories, Inc.. Products Portfolio

Table 40: Lake Immunogenics, Inc. Basic Information And Sales Area

Table 41: Lake Immunogenics, Inc.. Products Portfolio

Table 42: Rocky Mountain Biologicals Inc. Basic Information And Sales Area

Table 43: Rocky Mountain Biologicals Inc.. Products Portfolio

Table 44: ANZCO Foods Ltd. Basic Information And Sales Area

Table 45: ANZCO Foods Ltd.. Products Portfolio

Table 46: Auckland BioSciences Ltd. Basic Information And Sales Area

Table 47: Auckland BioSciences Ltd.. Products Portfolio

Table 48: Bovogen Biologicals Pty Ltd. Basic Information And Sales Area

Table 49: Bovogen Biologicals Pty Ltd.. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Type

Table 51: Global Market Share (%) By Type (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Animal Blood Plasma and Derivatives Market Value (USD Million) By Region

Table 55: Global Animal Blood Plasma and Derivatives Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Type

Table 58: North America Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Type

Table 61: Europe Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Type

Table 67: South America Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current Animal Blood Plasma and Derivatives market size?

The global Animal Blood Plasma and Derivatives market size surpassed USD 1.4 billion in 2023, propelled by rising demand for feed supplements, biologics, and cell-culture nutrients across livestock, veterinary, and life-science sectors.

2. What is the forecast CAGR and future outlook to 2030?

Analysts project a robust 7–8% CAGR through 2030, lifting the market beyond USD 2.3 billion; the future outlook remains bullish as plasma-based proteins increasingly replace antibiotics in animal husbandry.

3. What are the key drivers fueling growth?

Key drivers include intensifying protein demand, tightening antibiotic regulations, superior neonatal survival rates with plasma additives, and expanding aquaculture sectors seeking high-spec immunoglobulin concentrates.

4. Which challenges could restrain the market?

High raw-material cost volatility, biosecurity concerns over pathogen transmission, complex cold-chain logistics, and divergent global slaughter rates create supply constraints and pricing pressures for processors.

5. Which regions lead consumption and production?

North America and Europe dominate consumption owing to large-scale pig and calf rearing, while Latin America and Oceania emerge as low-cost production hubs benefitting from abundant slaughter volumes.

6. Who are the top companies shaping the competitive landscape?

Leaders include LAMPIRE Biological Laboratories, Rocky Mountain Biologicals, Thermo Fisher/Pfizer's Lake Immunogenics, Merck's Proliant Biologicals, BioChek, and European players Sanquin and Proliant Health, all investing in fractionation capacity.

7. Where do future opportunities lie?

Emerging opportunities sit in spray-dried plasma for aquafeed, pet-health nutraceuticals, and veterinary regenerative therapies; customized antibody-rich fractions for African swine fever or avian influenza prevention also promise high margins.

8. How is technology impacting production?

Advanced membrane chromatography, single-use bioreactors, and IoT-enabled cold-chain monitoring raise yield, purity, and shelf life while reducing water and energy use—critical for sustainable plasma fractionation.

9. What does the regulatory landscape look like?

Regulation is tightening: USDA/FSIS and EFSA now audit collection premises, while China mandates import registration for ruminant plasma; firms must validate prion removal steps and maintain Veterinary Health Certificates for cross-border shipments.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Animal Blood Plasma and Derivatives Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.03 billion
Revenue forecast in 2033	1.44 billion
Growth rate	CAGR of 4.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Proliant Inc.; Thermo Fisher Scientific, Inc.; Merck KGaA; Kraeber & Co GmbH; LAMPIRE Biological Laboratories, Inc.; Lake Immunogenics, Inc.; Rocky Mountain Biologicals Inc.; ANZCO Foods Ltd.; Auckland BioSciences Ltd.; Bovogen Biologicals Pty Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options